RXRX Stock Slips Onto Watchlists After Insider Form 144

Recursion Pharmaceuticals Inc. stocks have been trading down by -7.86 percent after unfavorable trial data dampened investor sentiment.

Live Update At 17:03:38 EDT: On Thursday, July 16, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending down by -7.86%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

RXRX has been bleeding lower over the past couple of weeks. The stock just closed near $3.02, down from recent highs around $4.09 earlier this month. That’s a steady grind lower, not a one-day crash, which tells traders sentiment has been softening in stages rather than panicking all at once.

Recursion Pharmaceuticals posted only about $74.7M in revenue over the last year, yet carries a price-to-sales ratio near 27. That’s a rich multiple for a company still deep in the red. RXRX’s gross margin is barely positive at 7.4%, while profit margins sit around -840%—massive losses for every dollar brought in.

The latest quarterly report shows a net loss of roughly $117.5M and negative free cash flow of about $81.4M. RXRX is burning cash fast, even though it still has a solid cushion with roughly $654M in cash and short-term investments and a strong current ratio of 5.5. For traders, that means Recursion Pharmaceuticals is a classic high-risk, high-upside biotech-style play, but right now the chart and the cash burn both lean bearish.

Why Traders Are Watching RXRX After The Form 144

The new twist for RXRX is the Form 144 filing. An insider or large shareholder at Recursion Pharmaceuticals has signaled they plan to sell restricted or control securities under SEC Rule 144. When someone close to the story lines up a sale, traders pay attention. It does not automatically mean disaster, but markets usually read it as a yellow flag.

Form 144 is basically a heads-up that shares may be coming to market. For RXRX, that means potential extra supply above the normal daily volume. Extra supply plus weak demand often equals pressure on the share price. With RXRX already sliding from the mid-$3s and $4s down toward $3.00, traders are going to be laser-focused on whether this news accelerates the drip lower or just gets absorbed quietly.

This matters even more because Recursion Pharmaceuticals is already a cash-burning machine. RXRX posted an EBITDA loss of about $102.4M last quarter, and operating cash flow came in around -$81.1M. That pace of spending leaves traders asking who blinks first: the bulls hoping for future AI-driven drug discovery breakthroughs, or the bears pointing to heavy dilution risk down the road.

On the intraday chart, RXRX spent most of the day chopping between $3.02 and $3.08, with a late-day fade to the $3.02 close. That tight, weak range shows no real buying conviction yet. When Form 144 headlines hit in that type of tape, short-biased traders often lean in, while long-biased day traders wait for an overreaction spike or a panic flush to trade against.

Conclusion

RXRX now sits at an interesting crossroads. Recursion Pharmaceuticals still has a big cash pile, modest debt, and a story that hooks growth-focused biotech traders. But the numbers are hard to ignore: steep negative margins, heavy quarterly losses, and a price tag that already bakes in a lot of future success. Add a fresh Form 144 from an insider or large holder, and you have a textbook recipe for a near-term overhang.

For active traders, RXRX is now a pure pattern and psychology play. Watch how the stock handles any uptick in volume around this Form 144 headline. If RXRX soaks up selling and holds $3.00, that tells you the market is willing to look past the filing. If Recursion Pharmaceuticals cracks that level on strong volume, the next leg lower can come faster than most traders expect.

This is where discipline matters. As Tim Sykes likes to remind his students, “The best traders are cowards — they respect risk, cut losses quickly, and always live to trade another day.” As millionaire penny stock trader and teacher Tim Sykes, says, “Cut losses quickly, let profits ride, and don’t overtrade.”. RXRX is a classic example. Recursion Pharmaceuticals can offer sharp intraday moves in both directions, but the only way to survive that volatility is to treat it as a trading vehicle, stick to your plan, and never confuse an exciting story with a guaranteed outcome.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks